ArticleRevista de neurologia2023

Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one.

D Fresán-Restituto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.